These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 31646375

  • 1. Radioembolization with 90Y Resin Microspheres of Neuroendocrine Liver Metastases After Initial Peptide Receptor Radionuclide Therapy.
    Braat AJAT, Ahmadzadehfar H, Kappadath SC, Stothers CL, Frilling A, Deroose CM, Flamen P, Brown DB, Sze DY, Mahvash A, Lam MGEH.
    Cardiovasc Intervent Radiol; 2020 Feb; 43(2):246-253. PubMed ID: 31646375
    [Abstract] [Full Text] [Related]

  • 2. Radioembolization with 90Y Resin Microspheres of Neuroendocrine Liver Metastases: International Multicenter Study on Efficacy and Toxicity.
    Braat AJAT, Kappadath SC, Ahmadzadehfar H, Stothers CL, Frilling A, Deroose CM, Flamen P, Brown DB, Sze DY, Mahvash A, Lam MGEH.
    Cardiovasc Intervent Radiol; 2019 Mar; 42(3):413-425. PubMed ID: 30603975
    [Abstract] [Full Text] [Related]

  • 3. 90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy.
    Ezziddin S, Meyer C, Kahancova S, Haslerud T, Willinek W, Wilhelm K, Biersack HJ, Ahmadzadehfar H.
    J Nucl Med; 2012 Nov; 53(11):1663-9. PubMed ID: 22988059
    [Abstract] [Full Text] [Related]

  • 4. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres.
    Paprottka PM, Hoffmann RT, Haug A, Sommer WH, Raessler F, Trumm CG, Schmidt GP, Ashoori N, Reiser MF, Jakobs TF.
    Cardiovasc Intervent Radiol; 2012 Apr; 35(2):334-42. PubMed ID: 21847708
    [Abstract] [Full Text] [Related]

  • 5. Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: A systematic review.
    Jia Z, Wang W.
    Eur J Radiol; 2018 Mar; 100():23-29. PubMed ID: 29496075
    [Abstract] [Full Text] [Related]

  • 6. Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0.
    Shady W, Kishore S, Gavane S, Do RK, Osborne JR, Ulaner GA, Gonen M, Ziv E, Boas FE, Sofocleous CT.
    Eur J Radiol; 2016 Jun; 85(6):1224-31. PubMed ID: 27161074
    [Abstract] [Full Text] [Related]

  • 7. 90Y Resin Microspheres Radioembolization for Colon Cancer Liver Metastases Using Full-Strength Contrast Material.
    Kurilova I, Beets-Tan RGH, Ulaner GA, Boas FE, Petre EN, Yarmohammadi H, Ziv E, Deipolyi AR, Brody LA, Gonen M, Sofocleous CT.
    Cardiovasc Intervent Radiol; 2018 Sep; 41(9):1419-1427. PubMed ID: 29766239
    [Abstract] [Full Text] [Related]

  • 8. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases.
    Jakobs TF, Hoffmann RT, Dehm K, Trumm C, Stemmler HJ, Tatsch K, La Fougere C, Murthy R, Helmberger TK, Reiser MF.
    J Vasc Interv Radiol; 2008 Aug; 19(8):1187-95. PubMed ID: 18656012
    [Abstract] [Full Text] [Related]

  • 9. Clinical and laboratory toxicity after intra-arterial radioembolization with (90)y-microspheres for unresectable liver metastases.
    Smits ML, van den Hoven AF, Rosenbaum CE, Zonnenberg BA, Lam MG, Nijsen JF, Koopman M, van den Bosch MA.
    PLoS One; 2013 Aug; 8(7):e69448. PubMed ID: 23894481
    [Abstract] [Full Text] [Related]

  • 10. 90Y Radioembolization in the Treatment of Neuroendocrine Neoplasms: Results of an International Multicenter Retrospective Study.
    Schaarschmidt BM, Wildgruber M, Kloeckner R, Nie J, Steinle V, Braat AJAT, Lohoefer F, Kim HS, Lahner H, Weber M, Theysohn J.
    J Nucl Med; 2022 May; 63(5):679-685. PubMed ID: 34475236
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients.
    Bester L, Meteling B, Pocock N, Pavlakis N, Chua TC, Saxena A, Morris DL.
    J Vasc Interv Radiol; 2012 Jan; 23(1):96-105. PubMed ID: 22079516
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Robust evidence for long-term survival with 90Y radioembolization in chemorefractory liver-predominant metastatic colorectal cancer.
    Jakobs TF, Paprottka KJ, Raeßler F, Strobl F, Lehner S, Ilhan H, Trumm CG, Fendler WP, Sommer W, Paprottka PM.
    Eur Radiol; 2017 Jan; 27(1):113-119. PubMed ID: 27059858
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Radioembolization with yttrium-90 resin microspheres for neuroendocrine tumor liver metastases.
    Peker A, Çiçek O, Soydal Ç, Küçük NÖ, Bilgiç S.
    Diagn Interv Radiol; 2015 Jan; 21(1):54-9. PubMed ID: 25430526
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.